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Antipsychotic treatment and neuregulin 1 -ErbB4 signalling in schizophrenia 
Abstract 
Evidence from genetic, transgenic and post-mortem studies has strongly supported the critical role that 
neuregulin 1 (NRG1) and its ErbB4 receptor plays in the pathophysiology of schizophrenia. This article 
aims to review current evidence regarding the effects of antipsychotic treatment on NRG1–ErbB4 
signalling. NRG1 and ErbB4 knockout mice display abnormal behaviours relevant to certain features of 
schizophrenia, which could be improved by antipsychotic (clozapine/haloperidol) treatment. In contrast to 
most NRG1/ErbB4 knockout mice with a decreased NRG1–ErbB4 signalling, the majority post-mortem 
studies showed an increased NRG1–ErbB4 signalling in schizophrenic patients. These differences could 
be due to degrees of alteration in risk genes (subtle variations in patients vs pronounced alteration in 
mutant mice) or the duration of the modification on NRG1 signalling. Various antipsychotics have 
different effects on NRG1 and ErbB4 expression and signalling that are dependent on treatment duration. 
Current evidence suggests that a chronic (12 weeks) antipsychotic treatment, at least in animal models, 
could downregulate NRG1–ErbB4 signalling, although an upregulation is seen for a short-term treatment. 
These effects may be due to multiple binding profiles with various G-coupled protein receptors (e.g. 
dopamine, and serotonin receptors) of antipsychotics. Studies are needed to investigate the interactions 
between NRG1–ErbB4 and the other signalling pathways (such as glutamatergic, GABAergic and 
dopaminergic). Furthermore, the interactions between NRG1/ErbB4 and other schizophrenia 
suspensibility genes under antipsychotic treatment also require investigation. 
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Evidence from genetic, transgenic and post-mortem studies have strongly supported 
the critical role that neuregulin 1 (NRG1) and its ErbB4 receptor play in the 
pathophysiology of schizophrenia. This article aims to review current evidence 
regarding to the effects of antipsychotic treatment on NRG1-ErbB4 signalling. NRG1 
and ErbB4 knockout mice display some schizophrenia-like behavioural abnormalities, 
which could be improved by antipsychotic (clozapine/haloperidol) treatment. In 
contrast to NRG1/ErbB4 knockout mice with a decreased NRG1-ErbB4 signalling, 
the majority post-mortem studies showed an increased NRG1-ErbB4 signalling in 
schizophrenia patients. These differences could be due to degrees of alteration in risk 
genes (subtle variations in patients vs pronounced alteration in mutant mice) or the 
duration of the modification on NRG1 signalling. Various antipsychotics have 
different effects on NRG1 and ErbB4 expression and signalling dependent on 
treatment duration. Current evidence suggests that a chronic (12 weeks) antipsychotic 
treatment, at least in animal models, downregulates NRG1-ErbB4 signalling, although 
an upregulation is seen for a short term treatment. Therefore, the dysfunctional 
NRG1-ErbB4 signalling observed in schizophrenia is unlikely to be due to 
antipsychotic therapy. Furthermore, multiple-receptor binding profiles (e.g. dopamine, 
and 5-HT receptors) of antipsychotics may also contribute to their different influences 
on NRG1-ErbB4 signalling. Studies are also needed to investigate the interactions 
between NRG1-ErbB4 and the other signalling pathways (such as glutamatergic, 
GABAergic and dopaminergic).  
 








5-HT, Serotonin; BA, Brodmann areas; BACE1, a transmembrane endopeptidase β-
Site APP-cleaving enzyme 1; CNS, central nervous system; CYT, C-terminal 
cytoplasmic tails; ErbB4, a membrane-associated tyrosine kinases, ErbB4 receptor 
kinases;  EGF, epidermal growth factor; Ig, immunoglobulin; NMDA, N-methyl-D-
aspartate; NRG1, neuregulin 1; PBLs, peripheral blood lymphocytes; PFC, prefrontal 
cortex; PPI, prepulse inhibition; PSD95, post synaptic density protein 95; SNP, 








Although the aetiology and pathophysiology of schizophrenia is still not fully 
understood, it has been widely accepted that both genetic and environmental factors 
play critical roles in the development of schizophrenia. Over the past decades, the 
roles of genetic factors have been attracting increased attentions in schizophrenia 
research. The neuregulin 1 (NRG1) gene has been identified as a candidate gene for 
schizophrenia in several genetics studies (Li et al., 2006; Liu et al., 2005; Petryshen et 
al., 2005; Stefansson et al., 2003; Williams et al., 2003; Yang et al., 2003). NRG1 is a 
group of proteins that contains an epidermal growth factor (EGF)-like domain (α or β) 
that signals by activating membrane-associated tyrosine kinases, especially the ErbB4 
receptor kinases in the central nervous system (CNS) (Falls, 2003). An association 
between ErbB4 gene and schizophrenia has also been reported (Silberberg et al., 
2006). NRG1-induced stimulation of the ErbB4 receptor plays critical roles in the 
neuronal functions that are closely related to the development of schizophrenia, 
mainly neuronal specification, neuronal migration, neuron-glial signalling, synapse 
formation, synaptic transmission, and plasticity of the CNS (for review: see Harrison 
and Law, 2006). Several studies found that animals with impaired NRG1-ErbB4 
signalling displayed schizophrenia-like behavioural abnormalities (Barros et al., 2009; 
Dejaegere et al., 2008; Rimer et al., 2005; Savonenko et al., 2008; Stefansson et al., 
2002). 
 
In clinics, various antipsychotic drugs, including typical and atypical antipsychotics, 
are widely used to control schizophrenia symptoms. Typical antipsychotics are 
effective to ameliorate the positive symptoms of schizophrenia mainly through 






Strange, 2008). Atypical antipsychotics have some effects on positive and negative 
symptoms, as well as cognitive deficits (Burton, 2006). Atypical antipsychotics have 
binding profiles not only with dopaminergic receptors, but also with many other 
receptors, including the serotonin (5-HT), α adrenergic, histamine H1, and muscarinic 
M1 receptors (Mathews and David, 2007). In view of the relationships between 
NRG1-ErbB4 function and the pathophysiology of schizophrenia, and between 
antipsychotic treatment and schizophrenia symptoms, the key questions are whether 
antipsychotic drugs regulate the NRG1-ErbB4 signalling, and how this regulation 
contributes to their efficacy in controlling schizophrenia symptoms? It is very 
interesting that schizophrenia patients with different NRG1 genotypes have been 
reported to respond differently to typical antipsychotics (Kampman et al., 2004). 
However, to date, not much attention has been paid on the effects of antipsychotic 
drugs on NRG1-ErbB4 signalling. This paper will focus on reviewing the current 




A reference search was performed across the Medline (January 2000 - November 
2010) and ScienceDirect (January 2000 - November 2010) databases. Key words 
included antipsychotic, individual drug names (chlorpromazine, trifluoperazine, 
perphenazine, triflupromazine, fluphenazine, thiothixene, zuclopenthixol, haloperidol, 
pimozide, melperone, loxapine, amisulpride, clozapine, risperidone, olanzapine, 
quetiapine, ziprasidone, aripiprazole, paliperidone, sulpiride, and zotepine), cross-
referenced with neuregulin 1, NRG1, and ErbB4. In addition, the reference lists of all 







3. Structures of NRG1 isoforms 
The NRG1 gene generates six types of protein (I-VI) and at least 31 isoforms in 
humans, presumably due to multiple promoters and alternative splicing; each protein 
type possesses a specific amino-terminal region. All six types of NRG1 isoforms have 
an EGF-like domain, which is located in the membrane-proximal area of the 
extracellular part. The type III isoforms contain a cysteine-rich domain (CRD) that 
has a transmembrane domain. In the NRG1 types I, II, IV and V isoforms, an 
immunoglobulin (Ig)-like domain connects with the N-terminal sequence and the 
EGF-like domain. However, the N-terminal sequence of NRG1 types III and VI is 
connected directly to the EGF-like domain. Then the EGF-like domain is connected 
with a C-terminal transmembrane domain with or without the linker regions. In the 
intracellular part, there are C-terminal regions (cytoplasmic tail) (Falls, 2003; 
Harrison and Law, 2006; Mei and Xiong, 2008). In the proteolytic processing of 
NRG1, a transmembrane endopeptidase β-Site APP-cleaving enzyme 1 (BACE1) is 
involved in cleaving the NRG1 molecule, releasing an extracellular domain of the 
NRG1 molecule (except in the case of NRG1 type III) (Hu et al., 2006; Willem et al., 
2006). In addition, the remaining membrane-bound NRG1 fragment can be cleaved by 
Aph1B/C-γ-secretase, generating an intracellular domain that can relocate into the 
nucleus to regulate gene transcription (Bao et al., 2003).  
 
4. Abnormal behaviours of animals with deficient NRG1-ErbB4 signalling could 
be reversed by antipsychotic treatment 
In the last decade, animal studies have shown that animals with abnormal NRG1-






hyperactivities in the novel open-field test and the alternating-Y maze (Barros et al., 
2009; Duffy et al., 2008; Gerlai et al., 2000; O'Tuathaigh et al., 2007; Rimer et al., 
2005; Stefansson et al., 2002; van den Buuse et al., 2009), deficits in prepulse 
inhibition (PPI) level (Barros et al., 2009; Dejaegere et al., 2008; Hong et al., 2008; 
Savonenko et al., 2008; Stefansson et al., 2002; van den Buuse et al., 2009), and 
lateral inhibition (Rimer et al., 2005), as well as impaired social activities 
(O'Tuathaigh et al., 2007). These reports provided evidence supporting the potential 
roles of mutations in NRG1 and ErbB4 genes as risk factors for schizophrenia. 
Importantly, some of the behavioural abnormalities caused by NRG1 and ErbB4 
knock-out could be normalised by administration of antipsychotics (Table 1). For 
example, it has been reported that treatment with clozapine can reverse the 
hyperactivity of NRG1 TMc-mutant mice in the novel open-field test and in the cross 
maze test (Stefansson et al., 2002). The effects of clozapine on suppressing 
hyperactivity have also been observed in open-field and running wheel tests in the 
NRG1 Ig-like domain mutant mice (Rimer et al., 2005), and in novelty-induced 
hyperactivity in BACE1-knockout mice. Although the deficits in PPI have been 
observed in NRG1 EGF- and BACE1-knockout mice, the effects of clozapine on 
improving PPI have been observed in BACE1-knockout mice (Savonenko et al., 
2008), but not in NRG1 EGF-mutant mice (Stefansson et al., 2002). Furthermore, 
deficits of PPI could be reversed to normal level both haloperidol or clozapine in 
Aph1B/C-γ-secretase-disturbed mice (Dejaegere et al., 2008). Impaired lateral 
inhibition in NRG1 Ig-like domain mutant mice could also be improved by clozapine 
(Rimer et al., 2005). In addition, clozapine could reverse the abnormalities in ErbB4-
deficient mice, including decreased anxiety in the open field test, more aggressive 







5. Dysregulated NRG1-ErbB4 signalling in schizophrenia: is it caused by 
antipsychotic treatment? 
A number of post-mortem studies examined the expression of NRG1 (including the 
protein level and its mRNA) in the brain of schizophrenia patients. Although the 
results are not completely consistent, they did provide evidence to show abnormal 
NRG1-ErbB4 signalling contributing to the pathophysiology of schizophrenia (Table 
2). Hashimoto et al. first reported an increase of the mRNA expression of NRG1 type 
I isoform, and a decrease in the ratios of type II/I and type II/III mRNA expressions in 
the prefrontal cortex (PFC) of schizophrenia patients (Hashimoto et al., 2004). These 
decreased rations of type II/I and type II/III expressions may indicate a relatively 
decreased expression of type II isoform in schizophrenia  (Hashimoto et al., 2004). In 
a following study, the levels of mRNA for NRG1 type I was confirmed to be elevated 
(34%) in the hippocampus of schizophrenia patients  (Law et al., 2006). Importantly, 
Chong et al. have also found that the protein level of the NRG1 intracellular part 
increased by about 20% only in the PFC of schizophrenia patients, but not in patients 
with bipolar disorders and depression (Chong et al., 2008). In contrast, a recent study 
demonstrated that the gene expression of NRG1 type I isoform decreased in the PFC, 
Brodmann area 10 (BA10) (53.2%), and the expression of NRG1 type II isoform 
increased in BA10 (193%) of elderly schizophrenia patients (Parlapani et al., 2010). 
In addition, the NRG1α mRNA expression was found to be decreased in the white 
matter and grey matter of the PFC in schizophrenia patients (Bertram et al., 2007). 
 
ErbB4 receptor expression was also shown to be abnormal in schizophrenia patients. 
A post-mortem study has shown that the protein expression of the full-length ErbB4 






al., 2008). In addition, another study has reported that the expression of ErbB4 
receptor isoforms that contain the C-terminal cytoplasmic tails (CYT)-1 domain 
significantly increased in the dorsolateral PFC of schizophrenia patients (Silberberg et 
al., 2006). Law and colleagues also pointed out that the mRNA of ErbB4 isoforms 
containing CYT-1 domain and a metalloprotease cleavable extracellular domain were 
promoted in the dorsolateral PFC of schizophrenia patients (Law et al., 2007). 
Interestingly, Hahn et al. (2006) have demonstrated that, although the expression of 
both NRG1 and ErbB4 receptors did not significantly change in the PFC in 
schizophrenic subjects compared to normal subjects, the phosphorylation and the 
activation of downstream signalling of the ErbB4 receptor was elevated. These results 
suggested an elevated NRG1-ErbB4 signalling in the brain of schizophrenia patients. 
 
NRG1 expression was also studied in the peripheral systems, and the results were not 
consistent. It was reported that the expression levels of NRG1 transcript variants in 
type I and type III isoforms significantly increased in peripheral blood lymphocytes 
(PBLs) from schizophrenia patients (Petryshen et al., 2005). However, another study 
reported a decrease of NRG1 mRNA expression in PBLs from schizophrenia patients 
(Zhang et al., 2008).  
 
In brief, although current reports are not completed consistent, the majority of studies 
in schizophrenia patients suggest an enhanced NRG1-ErbB4 signalling in 
schizophrenic patients through over expressions of NRG1 and ErbB4, or increased 
phosphorylation of the ErbB4 receptor leading to the elevated interaction of ErbB4 
and postsynaptic density protein 95 (PSD95). It has been suggested that enhanced 






et al., 2006). It should be noted that schizophrenia patients usually have undergone 
chronic antipsychotic treatments, therefore one key question is whether elevated 
NRG1-ErbB4 signalling observed in post-mortem studies is caused by antipsychotic 
treatment. However, current results do not support this claim, since the majority of 
post-mortem studies in schizophrenia have found no correlation between over-
expressions of NRG1/ErbB4 and dosages of antipsychotic treatment (Chong et al., 
2008; Hahn et al., 2006; Hashimoto et al., 2004; Law et al., 2007; Law et al., 2006). 
Furthermore, elevated expression of the NRG1 intracellular part was only observed in 
the PFC of schizophrenia, but not bipolar disorders and depression, although bipolar 
patients were also exposed to antipsychotics (Chong et al., 2008). Positive 
associations between intronic SNPs (rs7598440, rs707284, rs839523) and elevated 
mRNA expressions of ErbB4 isoforms containing a metalloprotease cleavable 
extracellular domain (JM-a) and CYT-1 domain have been reported, which suggests a 
splice-variant specific expression of ErbB4 in the brain in schizophrenia (Law et al., 
2007). Splice variant-specific alteration of NRG1 gene expression was also observed 
in schizophrenia (Law et al., 2006). It is important that chronic treatment of 
antipsychotics has been reported to decrease NRG1-ErbB4 signalling (Hahn et al., 
2006; Pan et al., 2010) (see below for details).  
 
6. The effects of antipsychotic treatment on NRG1-ErbB4 signalling  
Several studies (Table 3) have also demonstrated that NRG1-ErbB4 expression could 
be altered by administration of antipsychotic drugs in normal subjects. In an in vivo 
animal study, four-week treatment with haloperidol increased the expression of NRG1 
and ErbB4, while clozapine reduced the expression of NRG1 isoforms in the normal 
rat PFC (Wang et al., 2008). On the other hand, four-week treatment with both 






hippocampus (Wang et al., 2008). In the same study, four-week treatment with 
risperidone increased the protein levels of both NRG1 isoforms and ErbB4 receptors 
in the hippocampus, but not in the PFC (Wang et al., 2008). Additionally, in a clinical 
study, after a 2-week treatment with risperidone and quetiapine, NRG1 mRNA 
expression of PBLs of first-onset schizophrenia patients (who has not take 
antipsychotics before) significantly increased compared to the levels before 
antipsychotic drug therapies (Zhang et al., 2008). Moreover, an in vitro study has 
shown that NRG1 protein expression increased in human fetal brain aggregates after 
being exposed to clozapine for three weeks; however, the expression of NRG1 
proteins did not change following exposure to haloperidol (Chana et al., 2009). In 
addition to the finding that NRG1-induced ErbB4 activation was significantly 
enhanced in the PFC of schizophrenia patients (Hahn et al., 2006), it is very 
interesting that NRG1-induced ErbB4 activation was significantly reduced by a 12-
weeks treatment with haloperidol in mouse brains (Hahn et al., 2006).  Recently we 
examined the effects of short-term or chronic treatment with aripiprazole, haloperidol 
and olanzapine on the expression of NRG1 and ErbB4 in rat brains (Pan et al., 2010). 
We found that 1-week treatment with olanzapine significantly increased the protein 
expression of NRG1 type I, and type III in the hippocampus (unpublished data); 
however, 12-week treatment with aripiprazole and haloperidol significantly decreased 
the protein expression of NRG1 types I, II III and the ErbB4 receptor in the PFC. 
Haloperidol treatment for 12 weeks also significantly reduced NRG1 type III 
expression in the hypothalamus (Pan et al., 2010). These results suggested that, while 
relatively short-term (1-4 weeks) treatment with antipsychotics might increase the 
expression of NRG1 and ErbB4, chronic antipsychotic treatment (12 weeks) would 








In general, the proposition that dysregulation of NGR1-ErbB4 signalling is involved 





) mouse models and post-mortem brains of schizophrenia 
patients. However, findings from the knowout mouse models are contradictory to 
those findings obtained from post-mortem studies that, in contrast to NRG1/ErbB4 
mutant mice with a decreased NRG1-ErbB4 signalling that present schizophrenia-like 
abnormal behaviours, schizophrenia patients displayed an increased NRG1-ErbB4 
signalling. These differences are partly due to the fact that patients’ risk genotypes 
have only some subtle variations, while transgenic mice have a pronounced gene 
alteration (Banerjee et al., 2010), or partly due to the duration of the modification of 
NRG1 signalling (Savonenko et al., 2008). Furthermore, dysregulated NRG1-ErbB4 
signalling in schizophrenia might interact with other signalling pathways such as 
glutamatergic, GABAergic and dopaminergic pathways (Banerjee et al., 2010; 
Buonanno, 2010). It is important that antipsychotic drugs are able to reverse some 
abnormal behaviours in NRG1 and ErbB4 mutant mice, and affect the expression of 
NRG1/ErbB4 and the functioning of NRG1-ErbB4 signalling. It is worth noting that 
none of the antipsychotic drugs can directly act on ErbB4 receptors; the exact 
mechanisms of antipsychotics on NRG1-ErbB4 signalling are not clear. Although all 
antipsychotic drugs largely target dopamine receptors (Kapur and Mamo, 2003), 
atypical antipsychotics also have binding profiles on other receptors (such as 5-HT 
and cholinergic receptors), which might explain why various antipsychotics have 
different effects on NRG1 and ErbB4 expressions. Further studies investigating the 






NRG1/ErbB4 with other neurotransmitter systems, will improve our understanding of 
the aetiology of schizophrenia as well as the treatment of this devastating disease. 
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Table 1. Effects of antipsychotics on behavioural abnormalities in animals with impaired 
NRG1-ErbB4 signalling. 
 




Clozapine reversed the increased activity of the NRG1 TMc-mutant 
mice in the novel open-field test and T-maze test. 
Rimer et al., 
2005 
Clozapine 
The activity of the NRG1 Ig-mutant mice was affected by clozapine 





Haloperidol and clozapine normalised PPI deficit in Alph1 B/C γ-




Clozapine selectively normalised PPI deficits and attenuated 
novelty-induced hyperactivity occurring in BACE1-knockout mice. 
Barros et al., 
2009 
Clozapine 
Clozapine reversed the behavioural defects (such as decreased 
anxiety in the open field test, aggressive activities in the resident-














NRG1 expression in the CNS 
Hashimoto et al., 2004 
(1) NRG1 type I expression increased in the PFC of 
schizophrenia patients. 
(2) Type II/I and type II/III ratios decreased in the PFC of 
schizophrenia patients. 
Law et al., 2006 
NRG1 type I elevated in the PFC and the hippocampus in 
schizophrenia patients. 
Hahn et al., 2006 
The expression of NRG1 and the ErbB4 receptor was not 
different between schizophrenia patients and controls.  
Bertram et al. 2007 
The NRG1 isoform expression is significantly reduced in 
white matter and gray matter of the PFC of schizophrenia 
patients.  
Chong et al., 2008 
NRG1 expression increased in the PFC of schizophrenia 
patients. 
Parlapani et al., 2010 
(1) Expression of NRG1 type I decreased in BA10 of 
schizophrenia patients. 
(2) Expression of type II increased in BA10. 
NRG1 expression in the peripheral system 
Petryshen et al., 2005 
Expression of NRG1 type I and type III increased in PBLs of 
schizophrenia patients 
Zhang et al., 2008 
NRG1 expression in PBLs of schizophrenia patients was 
lower than control groups before any antipsychotic 
treatment. 
ErbB4 receptor expression 
Hahn et al., 2006 
ErbB4 expression in the brain of schizophrenia patients did 
not change, but the phosphorylation of the ErbB4 receptor 
elevated.  
Silberberg et al., 2006 
ErbB4 receptors isoforms that contain the CYT-1 domain 
over-expressed in the dorsolateral PFC of schizophrenia 
patients. 
Law et al. 2007 
The mRNA of ErbB4 isoforms containing CYT-1 and JM-a 
domain increased in the dorsolateral PFC of schizophrenia 
patients 
Chong et al., 2008 























NRG1 expression in PBLs of schizophrenia patients increased 
after quetiapine and risperidone treatment. 






Haloperidol increased the expression of NRG1 and ErbB4, 
clozapine decreased NRG1 expression in the rat PFC; 
haloperidol and clozapine increased NRG1and ErbB4 in the 
rat hippocampus; risperidone increased NRG1-ErbB4 
expression in the hippocampus. 





NRG1 expression in normal human fetal brain aggregates 
increased after exposure to clozapine, but not haloperidol. 
Hahn et al., 
2006 
 











Haloperidol reduced the NRG1-induced ErbB4 activation in 
mice brain. 
 
Aripiprazole and haloperidol decreased the protein expression 
of NRG1 types I, II III and the ErbB4 receptor in the rat PFC; 
haloperidol reduced NRG1 type III expression in the rat 
hypothalamus.  
